Back to Supplement Score
54
SCORE

Vinpocetine

Cerebral blood flow · PDE1 inhibitor · Memory · Regulatory grey area
Tier 3 — Trending

What it is

A semi-synthetic compound from periwinkle (vincamine derivative) that inhibits PDE1, dilates cerebral vessels, and has mild antiplatelet activity. Eastern European clinical trials (primarily Hungarian) show improvements in memory and cognitive recovery post-stroke. However, the FDA ruled in 1997 that vinpocetine is a pharmaceutical drug — not a legal dietary supplement — and has warned against its sale as a supplement. Banned in Canada, the UK, and Australia. Most trials are small, methodologically weak, and from a single research tradition. Safer cognitive options with better evidence exist (citicoline, phosphatidylserine, bacopa).

Efficacy
2/5
Safety
3/5
Research
2/5
Onset
4/5
Cost
4/5
Drug-int.
3/5

Dose

5–10 mg 3× daily (15–30 mg/day) with food if using; note that it is not a legal supplement in most Western countries

Time of day & tips

Legal status: not a legal supplement in the US, Canada, UK, or Australia — it is classified as a pharmaceutical drug. If using, take with food (fat-soluble). Avoid with anticoagulants, blood thinners, or before surgery — antiplatelet effects. Evidence-based cognitive alternatives (citicoline 250–500 mg/day) are preferable.

Cycling

Used in 3-month clinical cycles in Eastern European practice. Long-term safety and legality make cycling recommendations moot in most jurisdictions.

Compare or learn more

Compare with another supplement →
Browse by symptom →
Open the full interactive view →

Educational reference, not medical advice. About · Methodology · Privacy · Terms